Current medical therapies of breast cancer

François Duhoux Published in the journal : May 2017 Category : Congrès UCL de Médecine Générale

Summary :

CDK4/6 inhibitors are a new standard of care in the management of metastatic breast cancer patients. In the early setting, the use of genomic tests will better define the patients who will benefit the most from adjuvant chemotherapy.

Key Words

Breast cancer, CDK4/6 inhibitors, genomic tests